Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Indian Journal of Surgical Oncology
Erschienen in: Indian Journal of Surgical Oncology 4/2022

10.05.2022 | Review Article

Anti-cancer Activity of Chrysin in Cancer Therapy: a Systematic Review

verfasst von: Nader Salari, Farahnaz Faraji, Sima Jafarpour, Fatemeh Faraji, Shna Rasoulpoor, Sadat Dokaneheifard, Masoud Mohammadi

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Chrysin is a natural bioactive compound that is extracted from many trees, honey, and propolis. Chrysin has several pharmacological activities such as anti-inflammatory, anti-cancer, and antioxidant properties. This study was performed to evaluate the anti-cancer activities of chrysin in cancer therapy. The present study was conducted by systematic review of studies published up to August 2021. Related studies were identified by searching Web of Science (WoS), PubMed, Science Direct, SID, MagIran, Scopus, and Google Scholar databases. The keywords of chrysin, cancer, anti-cancer, and cancer therapy were used for searching. The quality of the studies was assessed by the CONSORT checklist. A total of 21 studies were identified. The results of studies showed that chrysin has an anticancer effect by stimulating apoptosis in a wide range of human cells and rats. Chrysin is also an important factor in inhibiting tumor growth and neoplasticity. Chrysin inhibits the growth and proliferation of cancer cells by inducing cytotoxic effects. Therefore, due to the antitumor effects of chrysin and its safety and non-toxicity towards normal cells, this compound can be considered as an adjuvant along with chemotherapeutic agents in cancer treatment.
Literatur
1.
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–74CrossRef
2.
Stratton M, Campbell P, Futreal P (2009) The cancer genome. Nat [Internet] 458(7239):719–724CrossRef
3.
Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ, Organization WH (2001) Cancer incidence, mortality and survival by site for 14 regions of the world
4.
Taheri NS, Nosrat SB, Aarabi M, Tabiei MN, Kashani E, Rajaei S et al (2012) Epidemiological pattern of breast cancer in Iranian women: is there an ethnic disparity? Asian Pac J Cancer Prev 13(9):4517–4520CrossRef
5.
Miller KD, Fidler-Benaoudia M, Keegan TH, Hipp HS, Jemal A, Siegel RL (2020) Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin 70(6):443–459CrossRef
6.
Rapta P, Mišík V, Staško A, Vrábel I (1995) Redox intermediates of flavonoids and caffeic acid esters from propolis: an EPR spectroscopy and cyclic voltammetry study. Free Radical Biol Med 18(5):901–908CrossRef
7.
Deledda A, Annunziata G, Tenore GC, Palmas V, Manzin A, Velluzzi F (2021) Diet-derived antioxidants and their role in inflammation, obesity and gut microbiota modulation. Antioxidants 10(5):708CrossRef
8.
Azman KF, Zakaria R (2019) Honey as an antioxidant therapy to reduce cognitive ageing. Iran J Basic Med Sci 22(12):1368
9.
Jaganathan SK, Mandal M (2009) Antiproliferative effects of honey and of its polyphenols: a review. J Biomed Biotechnol
10.
Brown E, Hurd NS, McCall S, Ceremuga TE (2007) Evaluation of the anxiolytic effects of chrysin, a Passifloraincarnata extract, in the laboratory rat. AANA J 75(5)
11.
Ghosh R, Alajbegovic A, Gomes AV (2015) NSAIDs and cardiovascular diseases: role of reactive oxygen species. Oxid Med Cell Longev 2015:536962CrossRef
12.
Williams CA, Harborne JB, Newman M, Greenham J, Eagles J (1997) Chrysin and other leaf exudate flavonoids in the genus Pelargonium. Phytochemistry 46(8):1349–1353CrossRef
13.
Chen Y-H, Yang Z-S, Wen C-C, Chang Y-S, Wang B-C, Hsiao C-A et al (2012) Evaluation of the structure–activity relationship of flavonoids as antioxidants and toxicants of zebrafish larvae. Food Chem 134(2):717–724CrossRef
14.
Gresa-Arribas N, Serratosa J, Saura J, Solà C (2010) Inhibition of CCAAT/enhancer binding protein δ expression by chrysin in microglial cells results in anti-inflammatory and neuroprotective effects. J Neurochem 115(2):526–536CrossRef
15.
Wang J, Qiu J, Dong J, Li H, Luo M, Dai X et al (2011) Chrysin protects mice from Staphylococcus aureus pneumonia. J Appl Microbiol 111(6):1551–1558CrossRef
16.
Villar IC, Jiménez R, Galisteo M, Garcia-Saura MF, Zarzuelo A, Duarte J (2002) Effects of chronic chrysin treatment in spontaneously hypertensive rats. Planta Med 68(09):847–850CrossRef
17.
Du Q, Gu X, Cai J, Huang M, Su M (2012) Chrysin attenuates allergic airway inflammation by modulating the transcription factors T-bet and GATA-3 in mice. Mol Med Rep 6(1):100–104
18.
Duarte J, Jiménez R, Villar IC, Pérez-Vizcaíno F, Jiménez J, Tamargo J (2001) Vasorelaxant effects of the bioflavonoid chrysin in isolated rat aorta. Planta Med 67(06):567–569CrossRef
19.
Torres-Piedra M, Ortiz-Andrade R, Villalobos-Molina R, Singh N, Medina-Franco JL, Webster SP et al (2010) A comparative study of flavonoid analogues on streptozotocin–nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11β-hydroxysteroid dehydrogenase type 1 inhibition. Eur J Med Chem 45(6):2606–2612CrossRef
20.
Critchfield JW, Butera ST, Folks TM (1996) Inhibition of HIV activation in latently infected cells by flavonoid compounds. AIDS Res Hum Retroviruses 12(1):39–46CrossRef
21.
Machala M, Kubínová R, Hořavová P, Suchý V (2001) Chemoprotective potentials of homoisoflavonoids and chalcones of Dracaena cinnabari: modulations of drug-metabolizing enzymes and antioxidant activity. Phytother Res 15(2):114–118CrossRef
22.
Pushpavalli G, Veeramani C, Pugalendi KV (2010) Influence of chrysin on hepatic marker enzymes and lipid profile against D-galactosamine-induced hepatotoxicity rats. Food Chem Toxicol 48(6):1654–1659CrossRef
23.
Anand KV, Mohamed Jaabir MS, Thomas PA, Geraldine P (2012) Protective role of chrysin against oxidative stress in d-galactose-induced aging in an experimental rat model. Geriatr Gerontol Int 12(4):741–750CrossRef
24.
Medina JH, Paladini AC, Wolfman C, de Stein ML, Calvo D, Diaz LE et al (1990) Chrysin (5, 7-di-OH-flavone), a naturally-occurring ligand for benzodiazepine receptors, with anticonvulsant properties. Biochem Pharmacol 40(10):2227–2231CrossRef
25.
Khoo BY, Chua SL, Balaram P (2010) Apoptotic effects of chrysin in human cancer cell lines. Int J Mol Sci 11(5):2188–2199CrossRef
26.
Zeng Y-B, Yang N, Liu W-S, Tang N (2003) Synthesis, characterization and DNA-binding properties of La (III) complex of chrysin. J Inorg Biochem 97(3):258–264CrossRef
27.
Rauf A, Khan R, Raza M, Khan H, Pervez S, De Feo V, Maione F, Mascolo N (2015) Suppression of inflammatory response by chrysin, a flavone isolated from Potentilla evestita Th. Wolf. In silico predictive study on its mechanistic effect. Fitoterapia 103:129–35CrossRef
28.
Pan M-H, Ho C-T (2008) Chemopreventive effects of natural dietary compounds on cancer development. Chem Soc Rev 37(11):2558–2574CrossRef
29.
Gonzalez CA, Riboli E (2010) Diet and cancer prevention: contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Eur J Cancer 46(14):2555–2562CrossRef
30.
Karthikeyan S, Srinivasan R, Wani SA, Manoharan S (2013) Chemopreventive potential of chrysin in 7, 12-dimethylbenz (a) anthracene-induced hamster buccal pouch carcinogenesis. Int J Nutr Pharmacol Neurol Dis 3(1):46CrossRef
31.
Xue C, Chen Y, Hu DN, Iacob C, Lu C, Huang Z (2016) Chrysin induces cell apoptosis in human uveal melanoma cells via intrinsic apoptosis. Oncol Lett 12(6):4813–4820CrossRef
32.
Samarghandian S, Afshari JT, Davoodi S (2011) Chrysin reduces proliferation and induces apoptosis in the human prostate cancer cell line pc-3. Clinics 66:1073–1079CrossRef
33.
Fu B, Xue J, Li Z, Shi X, Jiang B-H, Fang J (2007) Chrysin inhibits expression of hypoxia-inducible factor-1α through reducing hypoxia-inducible factor-1α stability and inhibiting its protein synthesis. Mol Cancer Ther 6(1):220–226CrossRef
34.
Shao JJ, Zhang AP, Qin W, Zheng L, Zhu YF, Chen X (2012) AMP-activated protein kinase (AMPK) activation is involved in chrysin-induced growth inhibition and apoptosis in cultured A549 lung cancer cells. Biochem X Biophys Res Commun 423(3):448–53CrossRef
35.
Yu XM, Phan T, Patel PN, Jaskula-Sztul R, Chen H (2013) Chrysin activates Notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma in vitro and in vivo. Cancer 119(4):774–781CrossRef
36.
Rehman MU, Tahir M, Khan AQ, Khan R, Lateef A, Oday OH et al (2013) Chrysin suppresses renal carcinogenesis via amelioration of hyperproliferation, oxidative stress and inflammation: plausible role of NF-κB. Toxicol Lett 216(2–3):146–158CrossRef
37.
Sun LP, Chen AL, Hung HC, Chien YH, Huang JS, Huang CY et al (2012) Chrysin: a histone deacetylase 8 inhibitor with anticancer activity and a suitable candidate for the standardization of Chinese propolis. J Agric Food Chem 60(47):11748–11758CrossRef
38.
Zhang T, Chen X, Qu L, Wu J, Cui R, Zhao Y (2004) Chrysin and its phosphate ester inhibit cell proliferation and induce apoptosis in Hela cells. Bioorg Med Chem 12(23):6097–6105CrossRef
39.
Zheng X, Meng WD, Xu YY, Cao JG, Qing FL (2003) Synthesis and anticancer effect of chrysin derivatives. Bioorg Med Chem Lett 13(5):881–884CrossRef
40.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1–9CrossRef
41.
Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Trials 11(1):1–8CrossRef
42.
Liu H, Liu K, Huang Z, Park C-M, Thimmegowda N, Jang J-H et al (2013) A chrysin derivative suppresses skin cancer growth by inhibiting cyclin-dependent kinases. J Biol Chem 288(36):25924–25937CrossRef
43.
Yang B, Huang J, Xiang T, Yin X, Luo X, Huang J et al (2014) Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway. J Appl Toxicol 34(1):105–112CrossRef
44.
Lirdprapamongkol K, Sakurai H, Abdelhamed S, Yokoyama S, Maruyama T, Athikomkulchai S et al (2013) A flavonoid chrysin suppresses hypoxic survival and metastatic growth of mouse breast cancer cells. Oncol Rep 30(5):2357–2364CrossRef
45.
Kasala ER, Bodduluru LN, Barua CC, Madhana RM, Dahiya V, Budhani MK et al (2016) Chemopreventive effect of chrysin, a dietary flavone against benzo (a) pyrene induced lung carcinogenesis in Swiss albino mice. Pharmacol Rep 68(2):310–318CrossRef
46.
Brechbuhl HM, Kachadourian R, Min E, Chan D, Day BJ (2012) Chrysin enhances doxorubicin-induced cytotoxicity in human lung epithelial cancer cell lines: the role of glutathione. Toxicol Appl Pharmacol 258(1):1–9CrossRef
47.
Li X, Huang J-M, Wang J-N, Xiong X-K, Yang X-F, Zou F (2015) Combination of chrysin and cisplatin promotes the apoptosis of Hep G2 cells by up-regulating p53. Chem Biol Interact 232:12–20CrossRef
48.
Ryu S, Lim W, Bazer FW, Song G (2017) Chrysin induces death of prostate cancer cells by inducing ROS and ER stress. J Cell Physiol 232(12):3786–3797CrossRef
49.
Rehman MU, Tahir M, Ali F, Khan AQ, Khan R, Lateef A et al (2012) Chrysin suppresses renal carcinogenesis via amelioration of hyperproliferation, oxidative stress and inflammation: plausible role of NF-? B. Free Radic Biol Med 53:S50CrossRef
50.
Khan MS, Devaraj H, Devaraj N (2011) Chrysin abrogates early hepatocarcinogenesis and induces apoptosis in N-nitrosodiethylamine-induced preneoplastic nodules in rats. Toxicol Appl Pharmacol 251(1):85–94CrossRef
51.
Zheng X, Meng W-D, Xu Y-Y, Cao J-G, Qing F-L (2003) Synthesis and anticancer effect of chrysin derivatives. Bioorg Med Chem Lett 13(5):881–884CrossRef
52.
Maruhashi R, Eguchi H, Akizuki R, Hamada S, Furuta T, Matsunaga T et al (2019) Chrysin enhances anticancer drug-induced toxicity mediated by the reduction of claudin-1 and 11 expression in a spheroid culture model of lung squamous cell carcinoma cells. Sci Rep 9(1):1–14CrossRef
53.
Lee S, Lee SK, Jung J (2021) Potentiating activities of chrysin in the therapeutic efficacy of 5‑fluorouracil in gastric cancer cells. Oncol Lett 21(1):1CrossRef
54.
Bahadori M, Baharara J, Amini E (2016) Anticancer properties of chrysin on colon cancer cells, in vitro and in vivo with modulation of caspase-3,-9, Bax and Sall4. Iran J Biotechnol 14(3):177CrossRef
55.
Song H-Y, Kim H-M, Mushtaq S, Kim WS, Kim YJ, Lim S-T et al (2019) Gamma-irradiated chrysin improves anticancer activity in HT-29 colon cancer cells through mitochondria-related pathway. J Med Food 22(7):713–721CrossRef
56.
Sun L-P, Chen A-L, Hung H-C, Chien Y-H, Huang J-S, Huang C-Y et al (2012) Chrysin: a histone deacetylase 8 inhibitor with anticancer activity and a suitable candidate for the standardization of Chinese propolis. J Agric Food Chem 60(47):11748–11758CrossRef
57.
Chen J, Wang Y, Zhao D, Zhang L, Zhang W, Fan J et al (2021) Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). Acta Pharmaceutica Sinica B 11(1):143–155CrossRef
58.
Zhang T, Chen X, Qu L, Wu J, Cui R, Zhao Y (2004) Chrysin and its phosphate ester inhibit cell proliferation and induce apoptosis in Hela cells. Bioorg Med Chem 12(23):6097–6105CrossRef
59.
Paciello F, Fetoni AR, Mezzogori D, Rolesi R, Di Pino A, Paludetti G et al (2020) The dual role of curcumin and ferulic acid in counteracting chemoresistance and cisplatin-induced ototoxicity. Sci Rep 10(1):1–17
60.
San TT, Khaenam P, Prachayasittikul V, Sripa B, Kunkeaw N, Chan-On W (2020) Curcumin enhances chemotherapeutic effects and suppresses ANGPTL4 in anoikis-resistant cholangiocarcinoma cells. Heliyon 6(1):e03255CrossRef
61.
Soni VK, Shukla D, Kumar A, Vishvakarma NK (2020) Curcumin circumvent lactate-induced chemoresistance in hepatic cancer cells through modulation of hydroxycarboxylic acid receptor-1. Int J Biochem Cell Biol 123:105752CrossRef
62.
Lu X, Yang F, Chen D, Zhao Q, Chen D, Ping H et al (2020) Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways. Int J Biol Sci 16(7):1121CrossRef
63.
Zhang W, Jiang H, Chen Y, Ren F (2019) Resveratrol chemosensitizes adriamycin-resistant breast cancer cells by modulating miR-122-5p. J Cell Biochem 120(9):16283–16292CrossRef
64.
Pichichero E, Cicconi R, Mattei M, Canini A (2011) Chrysin-induced apoptosis is mediated through p38 and Bax activation in B16–F1 and A375 melanoma cells. Int J Oncol 38(2):473–483
65.
Weng M-S, Ho Y-S, Lin J-K (2005) Chrysin induces G1 phase cell cycle arrest in C6 glioma cells through inducing p21Waf1/Cip1 expression: involvement of p38 mitogen-activated protein kinase. Biochem Pharmacol 69(12):1815–1827CrossRef
66.
Martins IsL, Charneira C, Gandin V, Ferreira da Silva JL, Justino GaC, Telo JoP et al (2015) Selenium-containing chrysin and quercetin derivatives: attractive scaffolds for cancer therapy. J Med Chem 58(10):4250–65CrossRef
67.
Xuan HZ, Zhang JH, Wang YH, Fu CI, Zhang W (2016) Anti-tumor activity evaluation of novel chrysin–organotin compound in MCF-7 cells. Bioorg Med Chem Lett 26(2):570–4CrossRef
68.
Khan MS, Halagowder D, Devaraj SN (2011) Methylated chrysin induces co-ordinated attenuation of the canonical Wnt and NF-kB signaling pathway and upregulates apoptotic gene expression in the early hepatocarcinogenesis rat model. Chem Biol Interact 193(1):12–21CrossRef
69.
Kasala ER, Bodduluru LN, Madana RM, Gogoi R, Barua CC (2015) Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives. Toxicol Lett 233(2):214–225CrossRef
70.
Rehman MU, Tahir M, Khan AQ, Khan R, Lateef A, Qamar W et al (2013) Chrysin suppresses renal carcinogenesis via amelioration of hyperproliferation, oxidative stress and inflammation: plausible role of NF-κB. Toxicol Lett 216(2–3):146–158CrossRef
71.
Sequetto PL, Oliveira TT, Soares ÍA, Maldonado IR, Mello VJ, Pizziolo VR et al (2013) The flavonoid chrysin attenuates colorectal pathological remodeling reducing the number and severity of pre-neoplastic lesions in rats exposed to the carcinogen 1, 2-dimethylhydrazine. Cell Tissue Res 352(2):327–339CrossRef
72.
Zhu Y, Yao X, Long J, Li R, Liu Y, Yang Z, et al (2019) Fluorine-containing chrysin derivatives: synthesis and biological activity. Nat Prod Commun 14(9):1934578X19878921
73.
Halevas E, Mavroidi B, Antonoglou O, Hatzidimitriou A, Sagnou M, Pantazaki AA et al (2020) Structurally characterized gallium–chrysin complexes with anticancer potential. Dalton Trans 49(8):2734–2746CrossRef
74.
Moghadam ER, Ang HL, Asnaf SE, Zabolian A, Saleki H, Yavari M et al (2020) Broad-spectrum preclinical antitumor activity of chrysin: current trends and future perspectives. Biomol 10(10):1374
Metadaten
Titel
Anti-cancer Activity of Chrysin in Cancer Therapy: a Systematic Review
verfasst von
Nader Salari
Farahnaz Faraji
Sima Jafarpour
Fatemeh Faraji
Shna Rasoulpoor
Sadat Dokaneheifard
Masoud Mohammadi
Publikationsdatum
10.05.2022
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 4/2022
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-022-01550-6

Weitere Artikel der Ausgabe 4/2022

Indian Journal of Surgical Oncology 4/2022 Zur Ausgabe

Point of Technique

Mandibular Swing Approach for Myositis Ossificans of the Lateral Pterygoid Muscle: A New Treatment Modality Explored

Original Article

Imaging Features of Breast Cancer Subtypes on Mammography and Ultrasonography: an Analysis of 479 Patients

Review Article

Laparoscopic vs Open Pancreaticoduodenectomy—an Updated Meta-Analysis of Randomized Control Trials

Original Article

Low-Grade Serous Ovarian Carcinoma: a Retrospective Study from a Tertiary Cancer Institute

Letter to the Editor

Gastric Gastro-intestinal Stromal Tumour Presenting as an Acute Perforation Peritonitis in a Young Male

Original Article

A Clinicopathological Correlation of Bladder Cancer in Young and Old Patients: Our Experience and Review of Literature

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.